For the quarter ending 2025-09-30, IBRX made $32,061K in revenue. -$67,253K in net income. Net profit margin of -209.77%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 32,061 | 26,425 | 16,517 | 7,552 |
| Cost of sales | 177 | 136 | 58 | 0 |
| Research and development-Nonrelated Party | 48,661 | 52,430 | 45,976 | - |
| Research and development (including amounts with related parties) | - | - | - | 35,221 |
| Research and development-Related Party | 2,571 | 2,806 | 2,258 | - |
| Selling, general and administrative (including amounts with related parties) | - | - | - | 41,731 |
| Selling, general and administrative-Nonrelated Party | 35,508 | 41,862 | 31,977 | - |
| Impairment of intangible assets | - | - | - | 0 |
| Selling, general and administrative-Related Party | 774 | 476 | 677 | - |
| Total operating costs and expenses | 87,691 | 97,710 | 80,946 | 76,952 |
| Loss from operations | -55,630 | -71,285 | -64,429 | -69,400 |
| Interest and investment income, net | 2,067 | 1,153 | 887 | 1,187 |
| Interest expense (including amounts with related parties) | - | - | - | 27,777 |
| Change in fair value of related-party convertible notes | - | - | - | 21,736 |
| Interest expense related to revenue interest liability | - | - | - | 31,446 |
| Interest expense (including amounts with related parties)-Related Party | 15,256 | 15,474 | 15,313 | - |
| Change in fair value of warrant liabilities | -14,905 | -3,889 | 448 | -9,733 |
| Interest expense related to revenue interest liability | 12,302 | 13,405 | 13,534 | - |
| Change in fair value of related-party convertible note-Related Party | -1,169 | 1,169 | -42,582 | - |
| Change in fair value of derivative liabilities | 289 | 1,931 | 5,578 | -6,607 |
| Loss on equity method investment | - | - | - | 0 |
| Interest expense (including amounts with related parties)-Nonrelated Party | 26 | 5 | 18 | - |
| Other (expense) income, net | -187 | -278 | -41 | 10 |
| Total other expense, net | -11,679 | -21,020 | -65,471 | 10,221 |
| Loss before income taxes and noncontrolling interests | -67,309 | -92,305 | -129,900 | -59,179 |
| Income tax benefit | -35 | 269 | -234 | 0 |
| Net loss | -67,274 | -92,574 | -129,666 | -59,179 |
| Net loss attributable to noncontrolling interests, net of tax | -21 | -19 | -20 | -17 |
| Net loss attributable to immunitybio common stockholders | -67,253 | -92,555 | -129,646 | -59,162 |
| Net loss per immunitybio common share basic (in dollars per share) | -0.07 | -0.1 | -0.15 | -0.07 |
| Net loss per immunitybio common share - diluted (in dollars per share) | -0.07 | -0.1 | -0.15 | -0.08 |
| Weighted-average number of common shares used in computing net loss per share basic (in shares) | 946,601,000 | 888,216,000 | 853,162,000 | -1,358,352,378 |
| Weighted-average number of common shares used in computing net loss per share diluted (in shares) | 946,601,000 | 888,216,000 | 853,162,000 | -1,357,287,378 |
ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX)